Revelation Biosciences reported a Q3 2024 net loss of $2.2 million, compared to a $2.6 million loss in Q3 2023. Revenue remained at zero while research and development expenses decreased to $0.8 million from $1.7 million YoY. The company ended the quarter with cash and cash equivalents of $6.5 million.The company raised $9.2 million during the first nine months through financing activities, including $5.4 million from a February 2024 public offering and $3.5 million from warrant inducement. Research and development efforts focused on advancing GEM-AKI for acute kidney injury, GEM-CKD for chronic kidney disease, and GEM-PSI for post-surgical infection prevention.Management expressed substantial doubt about the company's ability to continue as a going concern, noting current cash reserves will not sustain operations for the next 12 months. Additionally, Revelation received a Nasdaq delisting notice in October 2024 for failing to maintain the minimum bid price requirement, though the company has appealed and is pursuing compliance measures.

Revelation Biosciences reported a Q3 2024 net loss of $2.2 million, compared to a $2.6 million loss in Q3 2023. Revenue remained at zero while research and development expenses decreased to $0.8 million from $1.7 million YoY. The company ended the quarter with cash and cash equivalents of $6.5 million.The company raised $9.2 million during the first nine months through financing activities, including $5.4 million from a February 2024 public offering and $3.5 million from warrant inducement. Research and development efforts focused on advancing GEM-AKI for acute kidney injury, GEM-CKD for chronic kidney disease, and GEM-PSI for post-surgical infection prevention.Management expressed substantial doubt about the company's ability to continue as a going concern, noting current cash reserves will not sustain operations for the next 12 months. Additionally, Revelation received a Nasdaq delisting notice in October 2024 for failing to maintain the minimum bid price requirement, though the company has appealed and is pursuing compliance measures.